Tools   Select Another Resource Report Type

http://www.solvobiotech.com/

Commercial organization that is a worldwide provider of drug transporter technology, assays and reagents. Leveraging their expertise in efflux and uptake transporters, they generate quality reports for submission to FDA / EMA. From small molecules to protein therapeutics, SOLVO can test all transporter needs. Drug transporter Services and Products include: * Over 100 solutions for a wide range of transporters * Uptake transporter assays * Efflux transporter assays in cellular and membrane-based models * Transporter Consultancy Services * FDA- and EMA-ready reports * Ready-to-use Kits * In vitro and in vivo methods for studying transporters in the BBB, intestine, liver and kidney * Custom assay development

Proper citation: SOLVO Biotechnology (RRID:SCR_003964) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/show/NCT01211678

A consortium evaluating a new biomarker screening test that might help identify patients with rheumatoid arthritis (RA) who are unlikely to benefit from anti-tumor necrosis factor-alpha (TNFalpha) medications. BATTER-UP will enroll around 1,000 patients being treated by one of several marketed anti-TNF RA drugs: Enbrel, Remicade, Humira, Simponi, or Cimzia. Through data analyses and predictive response modeling, the consortium aims to better understand which patients with RA will derive the greatest benefit from TNF inhibitors. The investigators in this observational study will attempt to validate an 8-gene biomarker set based on work by Biogen Idec researchers as likely to predict anti-TNF responsiveness in patients with RA. In preliminary results, the 8-gene biomarker set predicted with 89% accuracy individuals who did not reach European League Against Rheumatism (EULAR) Disease Activity Score (DAS)-28 good response after 14 weeks of treatment. The 8 genes included in the screen are CLTB, MXRA7, CXorf52, COL4A3BP, YIPF6, FAM44A, SFRS2, and PGK1. Biological samples and clinical outcome information will be used to confirm and extend the utility of previously published biomarkers that can predict response to anti-TNF agents. These data may also generate new hypotheses for further testing. The BATTER-UP samples and data will be established as a reference set for investigation of personalized medicine in RA. The study will be a resource of DNA and other biological materials that can be investigated for biomarkers in the future as new technologies arise.

Proper citation: Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis - Unresponsive Populations (RRID:SCR_004019) Copy   

•   Source: SciCrunch Registry

http://sourceforge.net/projects/seqexpress/

A cross-platform software that estimates gene/isoform expression level via mRNA-Seq data. SeqExpress exams the Sequencing bias in mRNA-Seq and correct it to get more accurate estimation.

Proper citation: SeqExpress (RRID:SCR_004013) Copy   

•   Source: SciCrunch Registry

http://datacatalog.med.nyu.edu/

A searchable data catalog that facilitates researchers'' access to large datasets available either publicly or through institutional or individual licensing. Dataset records include information about the content of the dataset, how to access the dataset, and local experts within NYULMC and NYU to assist in the use of these datasets. The data catalog will expand to include internally generated datasets from NYULMC and NYU in the near future. Use the contact form if you are interested in submitting a dataset to the data catalog.

Proper citation: NYU Data Catalog (RRID:SCR_004012) Copy   

•   Source: SciCrunch Registry

http://www.westonfoundation.org/

Foundation that gives grants in Canada for the benefit of Canadians and directs its resources to specific organizations in Education, Land Conservation and Science in Canada''s North. In addition, it provides funds to further Canada''s research in neuroscience. These programs are director-initiated and the Foundation therefore does not accept applications for funding. By law, the Foundation is only able to support Canadian charities that are registered with the Canadian Revenue Agency. These charities must have a CRA charitable number and offer programs benefiting Canadians in Canada.

Proper citation: W. Garfield Weston Foundation (RRID:SCR_004017) Copy   

•   Source: SciCrunch Registry

http://www.cxrbiosciences.com/

Commercial organization that provides preclinical services and expertise, specializing in investigative toxicology, exploratory and discovery toxicology, metabolism and pharmacokinetics. CXR Biosciences is now Concept Life Sciences.

Proper citation: CXR Biosciences (RRID:SCR_003961) Copy   

•   Source: SciCrunch Registry

http://www.alz.org/research/alzheimers_grants/biomarkers-across.asp

Consortium that launched a Request for Applications (RFA) to stimulate analyses across the Alzheimer's disease (AD) and Parkinson's disease (PD) research enterprises to engage in further data analysis of existing cohorts, including, but not limited to, biomarker discovery, standardization of assays, genetic profiles, and imaging modalities. The RFA aims to build on existing momentum to leverage similar activities and increase impact across the neurodegenerative disease spectrum. It also builds on recent evidence suggesting substantial overlap between AD, PD, and other neurodegenerative diseases pathologically, but also potentially biologically. The RFA is designed to enable preliminary pilot research or proof-of-principle studies utilizing data and/or samples from two large biomarker studies, the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Parkinson's Progression Markers Initiative (PPMI), in order to garner further research support from other funding agencies. Application Deadline: March 19, 2014. Efforts under BAND include studies that: * analyze datasets to test hypotheses related to aging and neurodegenerative disorders; * seek to identify panels or pathways that may play a role in disease mechanisms, such as around inflammation; * pursue shared or disparate biochemical markers of disease risk, onset or progression; * assess potential commonalities across the disease spectrum, including around other neurological disorders such as Lewy body dementia. Recent data reported at the 2013 Alzheimer's Association's International Conference stimulated discussion in the research community about the possible cross talk between AD and PD. For example, underlying pathologies / biomarkers, such as cerebrospinal fluid (CSF) alpha-synuclein, have been measured in the sample sets collected for both diseases to help understand similarities and differences in these diseases. Furthermore, similar imaging modalities, such as MRI and PET, are being employed to interrogate changes that occur with disease progression. As therapeutic approaches are developed that may be disease-modifying for several neurodegenerative diseases, stratification of clinical trial populations based on biomarker profiles may increase the probability of success in demonstrating a beneficial effect.

Proper citation: Biomarkers Across Neurodegenerative Diseases (RRID:SCR_004015) Copy   

•   Source: SciCrunch Registry

http://www.gabo-mi.com/

THIS RESOURCE IS OUT OF SERVICE, documented on July 23, 2021. Small and medium-sized enterprise (SME) that is expert in management of research projects. Initially, they provide support with help and advice when applying for European research grants - free of charge. From project start, they take over contract negotiations, financial management, reporting to the EC, meeting organization, public relations and much more. ARTTIC Innovation GmbH took over GAVBO:mi.

Proper citation: GABO:mi (RRID:SCR_003956) Copy   

•   Source: SciCrunch Registry

http://www.interfaceurope.eu/

THIS RESOURCE IS OUT OF SERVICE, documented on July 23, 2021.Commercial organization with expertise in European research and innovation that provide both science providers (researchers) and technology users (Industry including SMEs, public authorities, Universities, clusters, etc.) tailor-made services to give the highest possible European added value to their project.

Proper citation: Interface Europe (RRID:SCR_003955) Copy   

•   Source: SciCrunch Registry

http://www.epo-berlin.com/

A small and medium-sized enterprise (SME) that has expertise in preclinical pharmacology, pharmacokinetics, and toxicology for the characterization of novel anticancer therapeutics and predictive biomarkers like: cytostatics, biologicals (peptides, antibodies), (anti)-hormones, immunomodulators (cytokines), and gene therapeutics. EPO has modern laboratories licensed for animal experiments and gene technology (S2) and a broad panel of murine and human tumor models growing in immunocompetent (SPF-quality, syngeneic strains) or immunodeficient mice (nude, SCID, NOD/SCID). EPO has established imaging technologies to monitor in vivo tumor growth.

Proper citation: Experimental Pharmacology and Oncology Berlin-Buch (RRID:SCR_003954) Copy   

•   Source: SciCrunch Registry

http://www.alacris.de/

Commercial organization that uses next generation sequencing technologies coupled with computational modeling of tumor and somatic tissues in order to identify individualized therapies for cancer patients. The company also uses these technologies to help pharmaceutical partners stratify patients for their clinical trials. Alacris has an exclusive worldwide commercial license for the computational modeling of tumors and somatic tissues using proprietary computational systems modeling technologies ModCell developed at the Max Planck Institute for Molecular Genetics (MPI-MG) in Berlin coupled with next generation sequencing and genotyping technology developed at Harvard Medical School in Boston. The company also is building up the first next generation sequencing center in Europe for clinical operations.

Proper citation: Alacris Theranostics (RRID:SCR_003953) Copy   

•   Source: SciCrunch Registry

http://psynova.com/

Commercial organization focused on the development and exploitation of novel biomarkers for psychiatric illnesses. They provide industrial and academic partners with comprehensive biomarker discovery services in commercial and collaborative projects. They operate in the field of psychiatric disorders and their products and services are designed to excel biomarker research. In 2010, Psynova Neurotech and its partner company Rules-Based-Medicine Inc (now MyriadRBM) conducted a beta launch of a blood test aiding in the diagnosis of schizophrenia (http://www.veripsych.com/). They are now refining the test and have shifted their focus to the development of new blood-based biomarker tests that aid in the diagnosis, prognosis and differential diagnosis of schizophrenia, bipolar disorder and major depression. They offer not only their pre-selceted Multiple Reaction Monitoring (MRM) and Multiplex Immunoassay products, but also custom build panels. If they are provided with a list of analyses to evaluate, they can produce an analytical panel according to individual needs utilizing either MRM or Multiplex Immunoassay technologies., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Psynova Neurotech (RRID:SCR_003959) Copy   

•   Source: SciCrunch Registry

http://www.thecommunityguide.org/uses/funding.html

http://www.thecommunityguide.org/uses/funding.html

Proper citation: Coordinating center for infectious diseases (RRID:SCR_003958) Copy   

•   Source: SciCrunch Registry

http://www.proconsortium.org/pro/

An ontological representation of protein-related entities by explicitly defining them and showing the relationships between them. Each PRO term represents a distinct class of entities (including specific modified forms, orthologous isoforms, and protein complexes) ranging from the taxon-neutral to the taxon-specific. The ontology has a meta-structure encompassing three areas: proteins based on evolutionary relatedness (ProEvo); protein forms produced from a given gene locus (ProForm); and protein-containing complexes (ProComp). NOTICE: The PRO ID format has changed from PRO: to PR: (e.g. PRO:000000563 is now PR:000000563).

Proper citation: PR (RRID:SCR_004964) Copy   

•   Source: SciCrunch Registry

http://wiki.iop.kcl.ac.uk/default.aspx/Neurodegeneration/Neurodegeneration%20Research%20Wiki.html

A wiki which provides information on neurodegenerative diseases to caregivers, students, and researchers.

Proper citation: Neurodegeneration Research Wiki (RRID:SCR_005015) Copy   

•   Source: SciCrunch Registry

http://www.uiowa.edu/

Public research university in Iowa City, Iowa. Founded in 1847, it is the oldest and the second-largest university in the state.

Proper citation: University of Iowa; Iowa; USA (RRID:SCR_005011) Copy   

•   Source: SciCrunch Registry

http://yost.genetics.utah.edu/software.php

A software analysis pipeline for mapping mutations using RNA-seq that works without parental strain information, without the requirement of a pre-existing snp map of the organism, and without erroneous assumptions that recombination occurs at the same frequency across the genome. In addition, it compensates for the considerable amount of noise in RNA-seq datasets and simultaneously identifies the region where the mutation lies and generates a list of putative coding region mutations in the linked genomic segment. MMAPPR can utilize RNA-seq datasets from isolated tissues or whole organisms that are often generated for phenotypic analysis and gene network analysis in novel mutants.

Proper citation: MMAPPR (RRID:SCR_005092) Copy   

•   Source: SciCrunch Registry

http://xml.coverpages.org/

Public reference database supporting the XML family of markup language standards, XML vocabularies, and related structured information standards. It promotes and enables the use of open, interoperable, standards-based solutions which protect digital information and enhance the quality of data processing. The Cover Pages web site provides reference material on enabling technologies compatible with SGML/XML descriptive markup language standards and applications: object modeling, semantic nets, ontologies, authority lists, document production systems, and conceptual modeling. It also supplies references for social aspects of distributed and public sector concerns: privacy, open standards, patented technology embedded in standards, etc. NB. This statement and the resource itself are works in progress, subject to continuous revision.

Proper citation: Cover Pages (RRID:SCR_004955) Copy   

•   Source: SciCrunch Registry

http://wellness.wikispaces.com/

Wellness Wiki is offered to help clarify the complex problems plaguing the U.S. healthcare system and develop sustainable ways to improve the health and well-being of all people. This virtual encyclopedia of the healthcare crisis and potential remedies welcomes your comments! The Wellness Wiki Book (Understanding & Curing American Healthcare: A Wise Way to Better Outcomes and Lower Costs) is available for purchase as a softcover book or pdf download. Table of contents: *Introduction & Executive Summary *Defining the Problem *Examining Three Proposed Solutions *Introducing a New Solution - Overview and Benefits, Wellness-Plus Solution Tactics, Barriers and Drivers to Implementing the Wellness-Plus Solution *Conclusion & Epilogue *Appendix *Wellness Model Technology Blueprint

Proper citation: Wellness Wiki (RRID:SCR_004957) Copy   

•   Source: SciCrunch Registry

http://www.mycobank.org/

Database documenting mycological nomenclatural novelties (new names and combinations) and associated data, for example descriptions and illustrations. The nomenclatural novelties will each be allocated a unique MycoBank number that can be cited in the publication where the nomenclatural novelty is introduced. These numbers will also be used by the nomenclatural database Index Fungorum, with which MycoBank is associated and will also serve as Life Science Identifiers (LSIDs). Nomenclatural experts will be available to check the validity, legitimacy and linguistic correctness of the proposed names in order to avoid nomenclatural errors; however, no censorship whatsoever, (nomenclatural or taxonomic) will be exerted by MycoBank. Deposited names will remain -when desired- strictly confidential until after publication, and will then be accessible through MycoBank, Index Fungorum, GBIF and other international biodiversity initiatives, where they will further be linked to other databases to realize a species bank that eventually will link all databases of life. MycoBank will (when applicable) provide onward links to other databases containing, for example, living cultures, DNA data, reference specimens and pleomorphic names linked to the same holomorph. Authors intending to publish nomenclatural novelties are encouraged to contribute to this new initiative. For the moment 2 search engines are available from the MycoBank website. The first one permits to search for fungal names (at any rank level), the authority or the MycoBank unique number. The second is dedicated to bibliographic queries related to fungal name''''s publications. MycoBank users willing to deposit their data will have to register so that they willbe able to contact the depositor for specific information (e.g. MycoBank number, possible points of attention regarding the name, actual publication, etc), and to avoid fake entries.

Proper citation: MycoBank (RRID:SCR_004950) Copy   

•   Source: SciCrunch Registry